Pyxis Oncology, Inc. Deferred Offering Costs
Pyxis Oncology, Inc. (PYXS) had Deferred Offering Costs of $1.10 million as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredOfferingCosts · last filed 2021-11-15
- 2021-09-30: Deferred Offering Costs $1.10M.
| Period end | Deferred Offering Costs |
|---|---|
| 2021-09-30 | $1.10M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |